Real Assets
We build future energy systems and resilient infrastructure, backing emerging opportunities in technology, land and water.
Technology
Industry
£3m
Aggregate investment by Foresight funds
2020
Initial investment date
Venture Capital
Investment type
Company background
Refeyn, a University of Oxford spin-out, develops and manufactures advanced mass photometry technology. This disruptive technology uses light to measure the mass of individual particles in solution, such as proteins and viruses, offering critical insights for scientific research, R&D, and therapeutic production. Originally launched in 2018, Refeyn’s compact, user-friendly instruments significantly reduce the time required for protein research and quality control, thereby cutting costs and accelerating drug development.
Investment
In 2019, Refeyn received £1.2 million from the Foresight Technology EIS Fund as part of a £3.5 million round led by Oxford Science Enterprises. The funds were used to commercialise the initial technology and support the development of further models, including a lower-cost “Lite” version and the “AutoMP” for high-throughput biopharma applications. Despite some delays, Refeyn successfully scaled operations, with its OneMP product being well-received in both academic and biotech sectors.
In April 2022, Refeyn completed an oversubscribed Series B funding round led by Northpond Ventures, positioning itself as a key player in biotherapeutics and expanding its mass photometry applications beyond bioanalytics.
Strategy
By 2025, Refeyn had installed over 500 instruments globally, contributing to more than 1,000 scientific papers. The company has also expanded its product line with the launch of the TwoMP, SamuxMP, and TwoMP Auto, further enhancing the performance and application range of mass photometry. Refeyn continues to grow as an international leader with offices in the US, China, and Japan.
